What is PROTAGENIC THERAPEUTICS's earnings per share (EPS)?

PROTAGENIC THERAPEUTICS (PTIX) reported diluted earnings per share of $0.59 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PROTAGENIC THERAPEUTICS (PTIX) Financials

PTIX

FY2026 annual

Revenue $0 YoY not available

Net Income $1.4M YoY not available

EPS (Diluted) $0.59 YoY not available

Free Cash Flow -$2.8M YoY not available

Market Cap $1.4M as of Oct 6, 2026

Price / Sales n/m revenue is not positive, FY2026

Price / Earnings 1.0x on $1.4M net income, FY2026

Price / Book 0.8x on $1.7M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PTIX SEC filings page.

PROTAGENIC THERAPEUTICS (PTIX) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTIX FY2026 2026-10-04

The latest accounts show operations still consume cash, while non-operating gains turned an operating loss into accounting profit.

In FY2026, a $4.5M operating loss coexisted with $1.4M net income because a negative interest line more than offset the operating shortfall; that is an accounting result, not evidence that core operations became profitable.

Profit did not convert to cash: FY2026 net income was $1.4M while operating cash flow was -$2.8M. Free cash flow was also -$2.8M, so reported profit did not fund operations or reinvestment.

By FY2026, equity had returned to positive at $2.6M while liabilities stood at $1.0M, reversing the prior negative-equity structure. Yet short-term balance-sheet slack narrowed: the current ratio fell from 6.4x in FY2023 to 1.5x in FY2026.

Financial Health Signals

Financial health score not available

PROTAGENIC THERAPEUTICS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-4.64

PROTAGENIC THERAPEUTICS scores -4.64, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.4M) relative to total liabilities ($1.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/6

PROTAGENIC THERAPEUTICS passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$2.05used

For every $1 of reported earnings, PROTAGENIC THERAPEUTICS used $2.05 of operating cash (-$2.8M OCF vs $1.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

PROTAGENIC THERAPEUTICS reported an operating loss of $4.5M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$953K

YoY+20.3%

PROTAGENIC THERAPEUTICS's EBITDA was -$953K in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.3% from the same quarter a year earlier.

Net Income

-$964K

YoY+80.9%

PROTAGENIC THERAPEUTICS reported -$964K in net income in Q1 2027. This represents an increase of 80.9% from the same quarter a year earlier.

EPS (Diluted)

-$0.53

QoQ-125.4%

PROTAGENIC THERAPEUTICS earned -$0.53 per diluted share (EPS) in Q1 2027. Against the prior quarter it is down 125.4%.

Revenue

Not reported for Q1 2027.

Cash & Balance Sheet

Cash & Debt

$566K

YoY-86.2%

QoQ-62.5%

5Y CAGR-45.6%

10Y CAGR-17.3%

PROTAGENIC THERAPEUTICS held $566K in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

PROTAGENIC THERAPEUTICS had 2M shares outstanding in Q1 2027.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Return on Equity

-55.9%

PROTAGENIC THERAPEUTICS's ROE was -55.9% in Q1 2027, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for Q1 2027.

Operating Margin

Not reported for Q1 2027.

Net Margin

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$110K

YoY-72.1%

PROTAGENIC THERAPEUTICS invested $110K in research and development in Q1 2027. This represents a decrease of 72.1% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2027.

Capital Expenditures

Not reported for Q1 2027.

PTIX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTIX quarterly income statement

Metric	TTM	FY2610-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	$0	$0	$0
R&D Expenses	N/A	$902K	$3.8M+25.5%	$3.1M+92.8%	$1.6M+39.8%	$1.1M+62.4%	$700K-13.4%	$808K-8.3%	$881K+22.8%	$717K+71.7%	$418K	N/A	N/A
SG&A Expenses	N/A	$332K	$1.8M+45.7%	$1.2M-38.7%	$2.0M-34.5%	$3.0M+62.2%	$1.9M+44.9%	$1.3M-10.8%	$1.4M-13.0%	$1.6M+16.7%	$1.4M	N/A	$101K
Operating Income	N/A	-$4.5M	-$5.7M-25.9%	-$4.5M-27.2%	-$3.6M+14.1%	-$4.1M-62.3%	-$2.6M-22.3%	-$2.1M+9.9%	-$2.3M+2.2%	-$2.4M-5.9%	-$2.2M	N/A	N/A
EBITDA	N/A	-$4.5M	-$5.7M-25.6%	-$4.5M-26.4%	-$3.6M	N/A	-$2.6M-22.3%	-$2.1M+9.9%	-$2.3M+2.2%	-$2.4M-5.9%	-$2.2M	N/A	N/A
Interest Expense	N/A	-$1.5M	-$1.0M-1065.2%	$108K-21.7%	$137K-72.3%	$497K+101.9%	$246K	N/A	N/A	N/A	$7K-37.6%	$11K+282.4%	$3K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	N/A	$1.4M	-$5.5M-10.5%	-$5.0M-40.6%	-$3.6M+21.4%	-$4.5M-77.5%	-$2.5M-45.6%	-$1.8M+31.5%	-$2.6M-13.2%	-$2.3M+0.7%	-$2.3M	N/A	N/A
EPS (Basic)	N/A	$0.59	-$1.13+1.7%	-$1.15-40.2%	-$0.82+33.9%	-$1.24	N/A	N/A	N/A	N/A	N/A	N/A	$0.00
EPS (Diluted)	$2.23	$0.59	-$1.13+1.7%	-$1.15-40.2%	-$0.82	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00
Diluted Shares (Avg)	N/A	2M	5M+12.8%	4M+0.6%	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	400M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	N/A	N/A	N/A	N/A	$0	$0	N/A	$0
R&D Expenses	$110K-72.1%	N/A	$154K+14.3%	$273K+1510.6%	$394K+1959.6%	N/A	$135K	$17K-98.5%
SG&A Expenses	$98K+95.6%	N/A	$155K+211.5%	$160K+626.0%	$50K+110.9%	N/A	$50K	$22K-92.8%
Operating Income	-$961K+20.5%	N/A	-$925K-130.5%	-$1.1M-213.4%	-$1.2M-275.5%	N/A	-$401K	-$355K+75.2%
EBITDA	-$953K+20.3%	N/A	-$913K-127.3%	-$1.1M-209.9%	-$1.2M-286.7%	N/A	-$401K	-$355K+75.2%
Interest Expense	$11K+104.5%	N/A	$24K+105.3%	$34K+114.4%	-$239K	N/A	-$449K	-$239K-847.0%
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3K
Net Income	-$964K+80.9%	N/A	$2.2M+360.0%	-$869K-49.3%	-$5.1M-1459.3%	N/A	-$850K	-$582K+58.3%
EPS (Basic)	-$0.53+61.3%	$2.09+176.0%	$1.14+812.5%	-$0.47-327.3%	-$1.37-2183.3%	-$2.75+49.4%	-$0.16+57.9%	-$0.11+65.6%
EPS (Diluted)	-$0.53	$2.09+176.0%	$1.14	-$0.47	-$1.37	-$2.75+49.4%	-$0.16+57.9%	-$0.11+65.6%
Diluted Shares (Avg)	2M	N/A	2M	2M	4M	523,185+65.1%	5M	5M+24.6%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

PTIX Balance Sheet

PTIX quarterly balance sheet

Metric	FY2610-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$3.7M	$2.0M-54.8%	$4.3M-46.2%	$8.0M-27.3%	$11.1M+1157.9%	$879K+4.4%	$842K+20.9%	$697K-60.9%	$1.8M-43.7%	$3.2M+28278.3%	$11K-58.5%	$27K
Current Assets	$1.5M	$1.9M-55.2%	$4.2M-47.7%	$8.0M-27.3%	$11.1M+1157.9%	$879K+4.4%	$842K+20.9%	$696K-60.9%	$1.8M-43.7%	$3.2M+94450.3%	$3K-85.3%	$23K
Cash & Equivalents	$1.5M	$80K-93.8%	$1.3M+498.5%	$215K-60.2%	$541K-19.4%	$671K-16.0%	$799K+120.3%	$362K-9.3%	$400K-87.1%	$3.1M+92643.0%	$3K-85.3%	$23K
Short-Term Investments	$0	$0-100.0%	$2.8M-64.3%	$7.8M-21.0%	$9.8M	$0	$0-100.0%	$250K-80.5%	$1.3M	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.0M	$5.3M+704.9%	$655K-41.5%	$1.1M+0.2%	$1.1M-44.9%	$2.0M+37.4%	$1.5M+62.7%	$908K+61.6%	$562K-18.0%	$685K+1.0%	$678K+357.6%	$148K
Current Liabilities	$1.0M	$943K+43.9%	$655K-41.5%	$1.1M+40.1%	$800K+22.0%	$655K-45.3%	$1.2M+31.9%	$908K+61.6%	$562K-18.0%	$685K+1.0%	$678K+357.6%	$148K
Non-Current Liabilities	$0	$4.3M	$0	$0-100.0%	$318K-76.8%	$1.4M+391.7%	$279K	$0	$0	$0	$0	$0
Total Equity	$2.6M	-$3.3M-190.5%	$3.7M-47.0%	$6.9M-30.4%	$9.9M+964.7%	-$1.1M-81.2%	-$634K-200.8%	-$211K-117.3%	$1.2M-50.8%	$2.5M+471.3%	-$667K-449.8%	-$121K
Retained Earnings	-$4.0M	-$36.3M-18.0%	-$30.8M-19.4%	-$25.8M-16.0%	-$22.2M-25.6%	-$17.7M-16.8%	-$15.2M-13.1%	-$13.4M-23.6%	-$10.8M-26.3%	-$8.6M-36.1%	-$6.3M-19.4%	-$5.3M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$2.8M-56.9%	$3.7M+3997.3%	$4.4M+126.5%	$5.0M+231.7%	$6.5M+342.3%	$89K-96.5%	$2.0M-54.8%	$1.5M-72.2%
Current Assets	$710K-83.6%	$1.5M+1631.4%	$2.3M+22.1%	$2.9M+100.9%	$4.3M+216.4%	$89K-96.4%	$1.9M-55.2%	$1.4M-73.5%
Cash & Equivalents	$566K-86.2%	$1.5M+10285.9%	$2.2M+2680.8%	$2.7M+3713.2%	$4.1M+474.0%	$15K+794.2%	$80K-93.8%	$71K-53.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Inventory	N/A	N/A	$1K	$1K	$1K	$1K	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.1M-89.7%	$1.0M-79.5%	$6.8M+29.4%	$9.7M+143.9%	$10.5M+224.9%	$5.0M+15.4%	$5.3M+704.9%	$4.0M+210.8%
Current Liabilities	$1.1M-89.7%	$1.0M-79.5%	$6.8M+623.8%	$9.7M+1129.3%	$10.5M+1451.0%	$5.0M+1030.3%	$943K+43.9%	$789K-38.3%
Non-Current Liabilities	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$4.3M	$3.2M
Total Equity	$1.7M+143.4%	$2.6M+152.9%	-$2.4M+27.9%	-$4.7M-90.3%	-$4.0M-126.7%	-$5.0M-176.8%	-$3.3M-190.5%	-$2.5M-159.5%
Retained Earnings	-$5.0M+52.2%	-$4.0M+25.3%	-$9.1M+74.9%	-$11.3M+67.4%	-$10.5M+69.3%	-$5.4M+83.4%	-$36.3M-18.0%	-$34.7M-19.4%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

PTIX Cash Flow Statement

PTIX quarterly cash flow statement

Metric	TTM	FY2610-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$2.0M	-$2.8M	-$4.2M-13.8%	-$3.7M-85.8%	-$2.0M+28.8%	-$2.8M-107.5%	-$1.3M-176.4%	-$488K+54.4%	-$1.1M+22.4%	-$1.4M-21.0%	-$1.1M	N/A	N/A
Depreciation & Amortization	N/A	$49K	$50K+78.2%	$28K+93960.0%	$30	N/A	$286-15.6%	$339-2.3%	$347+134.5%	$148-72.3%	$534+273.4%	$143-62.4%	$380
Stock-Based Compensation	N/A	$419K	$923K+38.4%	$667K-22.9%	$865K-43.1%	$1.5M-8.2%	$1.7M+107.4%	$798K-29.4%	$1.1M+27.2%	$888K+62.6%	$546K+14.1%	$479K+462.0%	$85K
Capital Expenditures	N/A	$3K	N/A	$150K+8197.8%	$2K	N/A	N/A	N/A	N/A	N/A	N/A	$2K+79.1%	$1K
Free Cash Flow	N/A	-$2.8M	N/A	-$3.9M-93.1%	-$2.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$630K	$2.8M-41.3%	$4.8M+199.0%	$1.6M+116.1%	-$9.9M	N/A	$250K-76.1%	$1.0M+181.3%	-$1.3M	N/A	N/A	N/A
Financing Cash Flow	N/A	$3.9M	$2.0M	N/A	N/A	$12.6M+928.1%	$1.2M+82.6%	$670K	N/A	N/A	$4.3M	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$944K+46.1%	$266K	-$510K+37.8%	-$812K-337.1%	-$1.8M-610.6%	N/A	-$820K+28.4%	-$186K+71.7%
Depreciation & Amortization	$8K-33.9%	$12K-8.5%	$13K	$13K	$13K0.0%	$13K0.0%	$0-100.0%	$0-100.0%
Stock-Based Compensation	$67K-46.4%	N/A	N/A	N/A	$125K	$236K+45.8%	N/A	N/A
Investing Cash Flow	N/A	-$313K	$0	$0	$943K-41.1%	N/A	$0-100.0%	$0-100.0%
Financing Cash Flow	N/A	-$534K-620.8%	-$2-100.0%	-$599K-289.1%	$5.0M+420.1%	$103K	$1.6M	$317K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

PTIX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTIX quarterly financial ratios

Metric	FY2610-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Return on Equity	52.2%	N/A	-136.3%-84.9pp	-51.4%-5.9pp	-45.5%	N/A	N/A	N/A	-185.3%-93.4pp	-91.9%	N/A	N/A
Return on Assets	37.5%	-282.5%-166.8pp	-115.7%-71.4pp	-44.2%-3.4pp	-40.9%+249.0pp	-289.9%-82.0pp	-207.9%+159.1pp	-367.0%-240.1pp	-126.9%-54.9pp	-72.0%	N/A	N/A
Current Ratio	1.50	2.00-4.4x	6.41-0.8x	7.18-6.7x	13.83+12.5x	1.34+0.6x	0.70-0.1x	0.77-2.4x	3.17-1.4x	4.62+4.6x	0.00-0.1x	0.15
Debt-to-Equity	0.39	N/A	0.180.0x	0.160.0x	0.11	N/A	N/A	N/A	0.46+0.2x	0.28	N/A	N/A
Asset Turnover	0.00	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Return on Equity	-55.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-34.5%+43.5pp	N/A	49.9%+93.4pp	-17.4%+21.2pp	-78.0%-55.8pp	N/A	-43.5%	-38.6%-12.9pp
Current Ratio	0.66+0.2x	1.50+1.5x	0.34-1.7x	0.29-1.5x	0.41-1.6x	0.02-5.5x	2.00-4.4x	1.80-2.4x
Debt-to-Equity	0.62	0.39	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PROTAGENIC THERAPEUTICS PTIX	FY2026	$0	$1.4M	N/A	$1.4M	—
GT Biopharma Inc. GTBP	FY2025	N/A	-$28.4M	N/A	$11.2M	—
Salarius Pharmaceuticals, Inc. SLRX	FY2025	N/A	$12.5M	N/A	$4.9M	—
Enveric Biosciences, Inc. ENVB	FY2025	N/A	$12.1M	N/A	$6.7M	—
Indaptus Therapeutics, Inc. INDP	FY2025	N/A	-$20.8M	N/A	$301.1M	—
SciSparc Ltd. SPRC	FY2025	$856K	-$12.6M	N/A	$2.7M	—

Where PROTAGENIC THERAPEUTICS Ranks

Frequently Asked Questions

What is PROTAGENIC THERAPEUTICS's annual revenue?

PROTAGENIC THERAPEUTICS (PTIX) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is PROTAGENIC THERAPEUTICS profitable?

Yes, PROTAGENIC THERAPEUTICS (PTIX) reported a net income of $1.4M in fiscal year 2026.

What is PROTAGENIC THERAPEUTICS's EBITDA?

PROTAGENIC THERAPEUTICS (PTIX) had EBITDA of -$4.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is PROTAGENIC THERAPEUTICS's return on equity (ROE)?

PROTAGENIC THERAPEUTICS (PTIX) has a return on equity of 52.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is PROTAGENIC THERAPEUTICS's free cash flow?

PROTAGENIC THERAPEUTICS (PTIX) recorded an outflow of $2.8M in free cash flow during fiscal year 2026. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is PROTAGENIC THERAPEUTICS's operating cash flow?

PROTAGENIC THERAPEUTICS (PTIX) recorded an outflow of $2.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are PROTAGENIC THERAPEUTICS's total assets?

PROTAGENIC THERAPEUTICS (PTIX) had $3.7M in total assets as of fiscal year 2026, including both current and long-term assets.

What are PROTAGENIC THERAPEUTICS's capital expenditures?

PROTAGENIC THERAPEUTICS (PTIX) invested $3K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does PROTAGENIC THERAPEUTICS spend on research and development?

PROTAGENIC THERAPEUTICS (PTIX) invested $902K in research and development during fiscal year 2026.

What is PROTAGENIC THERAPEUTICS's current ratio?

PROTAGENIC THERAPEUTICS (PTIX) had a current ratio of 1.50 as of fiscal year 2026, which is considered adequate.

What is PROTAGENIC THERAPEUTICS's debt-to-equity ratio?

PROTAGENIC THERAPEUTICS (PTIX) had a debt-to-equity ratio of 0.39 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is PROTAGENIC THERAPEUTICS's return on assets (ROA)?

PROTAGENIC THERAPEUTICS (PTIX) had a return on assets of 37.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is PROTAGENIC THERAPEUTICS's P/E ratio?

PROTAGENIC THERAPEUTICS (PTIX) trades at 1.0x earnings, its market capitalization divided by net income of $1.4M net income, FY2026. The market capitalization is $1.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PROTAGENIC THERAPEUTICS's price-to-sales ratio?

PROTAGENIC THERAPEUTICS (PTIX) has no price-to-sales ratio at the moment: revenue is not positive (FY2026). The market capitalization is $1.4M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does PROTAGENIC THERAPEUTICS's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, PROTAGENIC THERAPEUTICS (PTIX) held $1.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is PROTAGENIC THERAPEUTICS's Altman Z-Score?

PROTAGENIC THERAPEUTICS (PTIX) has an Altman Z-Score of -4.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is PROTAGENIC THERAPEUTICS's Piotroski F-Score?

PROTAGENIC THERAPEUTICS (PTIX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PROTAGENIC THERAPEUTICS's earnings high quality?

For every $1 of reported earnings, PROTAGENIC THERAPEUTICS (PTIX) used $2.05 of operating cash (-$2.8M OCF vs $1.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can PROTAGENIC THERAPEUTICS cover its interest payments?

PROTAGENIC THERAPEUTICS (PTIX) reported an operating loss of $4.5M against $1.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.